NEW DELHI: Biocon Biologics India Ltd expects its earnings to recover in April-June after the coronavirus pandemic disrupted its global operations in the previous quarter, pharmaceutical major Biocon Ltd subsidiary’s chief executive officer (CEO), Christiane Hamachar, told Mint in an interview. “Based on the sales trajectory of the past seven quarters, we see Q4 FY20 (January-March) as a one-time dip, we have reported a very strong annual growth of 29% and we remain on track for $1 billion by the end of fiscal year 2022.
While Q4 was a one-off, we expect recovery in Q1 (April-June) and then back to growth from Q2 (July-September)," Hamachar said.